Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
2020 · Annals of Oncology · 177 citations
https://doi.org/10.1016/j.annonc.2020.05.001